Ancora Advisors, LLC Moderna, Inc. Transaction History

Ancora Advisors, LLC

$3.98 Billion
Q1 2024

A detailed history of Ancora Advisors, LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Ancora Advisors, LLC holds 236 shares of MRNA stock, worth $28,025. This represents 0.0% of its overall portfolio holdings.

Number of Shares

236

Previous 236 -0.0%

Holding current value

$28,025

Previous $23,000 8.7%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$69.51 - $104.43 $4,865 - $7,310	-70 Reduced 22.88%	236 $23,000
Q2 2023 Aug 14, 2023	SELL	$118.5 - $160.53 $2,725 - $3,692	-23 Reduced 6.99%	306 $37,000
Q1 2023 May 15, 2023	BUY	$135.66 - $197.02 $13,023 - $18,913	96 Added 41.2%	329 $50,000
Q3 2022 Nov 14, 2022	BUY	$118.07 - $194.18 $1,652 - $2,718	14 Added 6.39%	233 $28,000
Q2 2022 Aug 15, 2022	SELL	$117.13 - $176.59 $117 - $176	-1 Reduced 0.45%	219 $31,000

Q1 2022 May 16, 2022	SELL	$126.46 - $235.05 $56,401 - $104,832	-446 Reduced 66.97%	220 $38,000
Q1 2022 May 13, 2022	BUY	$126.46 - $235.05 $56,401 - $104,832	446 Added 202.73%	666 $87,000
Q4 2021 Feb 14, 2022	BUY	$225.82 - $368.51 $903 - $1,474	4 Added 1.85%	220 $56,000
Q3 2021 Nov 15, 2021	SELL	$221.9 - $484.47 $122,045 - $266,458	-550 Reduced 71.8%	216 $83,000
Q2 2021 Aug 13, 2021	BUY	$129.91 - $234.98 $12,991 - $23,498	100 Added 15.02%	766 $180,000
Q1 2021 May 14, 2021	BUY	$109.18 - $185.98 $109 - $185	1 Added 0.15%	666 $87,000
Q3 2020 Nov 13, 2020	BUY	$54.34 - $94.85 $6,249 - $10,907	115 Added 20.91%	665 $47,000
Q1 2020 May 14, 2020	BUY	$17.78 - $31.58 $9,779 - $17,369	550 New	550 $16,000

Others Institutions Holding MRNA

# of Institutions

1,036

Shares Held

245M

Call Options Held

12.1M

Put Options Held

9.36M

View Full List

About Moderna, Inc.

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $46.5B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

More about MRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ancora Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ancora Advisors, LLC with notifications on news.

Account

Ancora Advisors, LLC Moderna, Inc. Transaction History